Previous Article | Next Article ![]()
Journal of Clinical Microbiology, April 2001, p. 1494-1500, Vol. 39, No. 4
Department of Microbiology, National
University of Ireland, Galway, Ireland,1
and Department of Bacteriology and Immunology, University
of Helsinki, Finland2
Received 4 October 2000/Returned for modification 14 December
2000/Accepted 26 January 2001
Mimicry of peripheral nerve gangliosides by Campylobacter
jejuni lipopolysaccharides (LPSs) has been proposed to
induce cross-reacting antiganglioside antibodies in
Guillain-Barré syndrome (GBS). Because current methods for LPS
characterization are labor-intensive and inhibit the screening of large
numbers of strains, a rapid GM1 epitope screening assay was
developed. Biomass from two agar plates of confluent growth yielded
sufficient LPS using a novel phenol-water and ether extraction
procedure. Extracts of LPS were reacted with cholera toxin
(GM1 ligand), peanut agglutinin (Gal There is mounting evidence that
Campylobacter jejuni, a causative agent of enteritis, plays
a significant role in the development of Guillain-Barré syndrome
(GBS), a demyelinating disease of the peripheral nervous system
(26, 33, 49, 51). Several variants of GBS occur and
include the demyelinating form called acute inflammatory demyelinating
polyneuropathy (AIDP), the axonal form represented by acute motor
axonal neuropathy (AMAN), and an ocular variant termed Miller Fisher
syndrome (MFS) (18, 34). Characteristically, 76% of AMAN
and 42% of AIDP patients have serologic evidence consistent with
recent C. jejuni infection (18, 27).
O (Penner) serotyping distinguishes between C. jejuni
strains on the basis of differences in the saccharide structure (O side chain and core oligosaccharide [OS]) of the lipopolysaccharide (LPS)
of the bacterium (28, 38, 41). Some reports suggest that
only specific C. jejuni serotypes are associated with GBS (30, 45). In a Japanese study, 81% of C. jejuni isolates from GBS patients belonged to serotype O:19
(20), and, other studies have shown an association with
other serotypes (19, 31, 33, 37, 45, 48, 58). Autoreactive
antibodies to gangliosides, especially GM1, are found in
30% of GBS patient sera, particularly after C. jejuni
infection (15, 19, 26, 35, 36, 49, 58, 59, 63). Thus, it
is currently hypothesized that antiganglioside antibodies may be
induced as a result of molecular mimicry of peripheral nerve
gangliosides by structurally similar C. jejuni LPSs
(49, 59).
Furthermore, since anti-GM1 antibodies in human sera are
likely to be a contributory factor in GBS development, an important step in elucidating the pathogenesis of the disease is determining the
structure of the immunogenic epitopes in ganglioside-mimicking C. jejuni LPS. However, the LPSs from only a few
C. jejuni GBS or MFS isolates have been studied at the
chemical level to determine the precise nature of the ganglioside-like
structures (3, 5, 7, 8, 10, 29, 39, 48, 61). Methods used
for detecting and analyzing LPS are both labor-intensive and
time-consuming. The major difficulty is that large amounts of LPS are
required for chemical characterization, and this does not allow for the screening of large numbers of strains. However, serological analysis using antiganglioside antibodies and ligands has proven a useful approach for analysis of mimicry in C. jejuni LPS (39,
40, 49). Importantly, although GBS-associated strains can
express high-molecular-weight (high-Mr) LPS
(5, 6, 7), serological analysis using thin-layer
chromatography (TLC) can detect ganglioside mimicry in the core OS of
LPS (39, 40, 49).
The aim of this study was to develop a rapid screening test to detect
strains that have a GM1-like epitope in their LPSs. The
assay combined a rapid miniphenol-water extraction procedure with TLC
and immunostaining. The conformation of the carbohydrate moiety of
glycolipids is best preserved in TLC, which is thus an appropriate
technique for an assay examining reactions of antibodies with LPS. The
novel assay system was validated by comparing the data from binding
studies using purified LPS with results obtained using LPSs extracted
by the rapid method from the same C. jejuni strains. Only a
limited number of serotypes have been found in association with GBS,
and to answer the question whether ganglioside-like epitopes are
limited to a few C. jejuni serotypes, a collection of
C. jejuni serostrains was screened for the GM1
epitope using the new assay system. Finally, the technique was
applied to the rapid screening of clinical isolates from GBS and
enteritis patients.
(A preliminary report of this research was presented at the 10th
International Workshop on Campylobacter, Helicobacter and Related Organisms, Baltimore, Md., 12 to 16 September 1999.)
Bacterial strains and growth conditions.
Details of the
C. jejuni culture collection strains and clinical isolates,
as well as strains of Helicobacter pylori and
Escherichia coli used in this study, are given in Table
1. In addition, 59 C. jejuni
serostrains were also included in the study. C. jejuni and
H. pylori strains were routinely grown on blood agar
(Columbia Agar Base [Oxoid Ltd., London, England] with 10% unlysed
horse blood) at 37°C for 48 h in a H2-enriched
microaerobic atmosphere (GasPak BR38 [Oxoid] without a catalyst)
according to an established protocol (22). E. coli strain J5 was grown in an aerobic atmosphere on tryptone soya
agar (Oxoid) at 37°C for 24 h. C. jejuni strains used
for validation purposes (Table 2) were grown on blood agar in a manner
identical to that described above. Bacterial biomass was harvested, and
bulk extraction of LPS was performed by the hot phenol-water extraction
procedure as described previously (32, 55).
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.4.1494-1500.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Development of an Immunoassay for Rapid Detection of Ganglioside
GM1 Mimicry in Campylobacter jejuni
Strains
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
1
3GalNAc ligand),
and anti-GM1 antibodies. After the assay was validated, 12 of 59 (20%) C. jejuni serostrains, including four
serotypes that have not previously been associated with GBS, reacted
with two or more anti-GM1 ganglioside reagents.
Subsequently, LPS extracts from 5 of 7 (71%) C. jejuni
isolates and 2 of 3 (67%) C. jejuni culture collection
strains bore GM1 structures. Overall, the assay system was
reliable, efficient, and reproducible and may be adapted for
large-scale epidemiological studies.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
C. jejuni strains used in this study
Biotyping and serotyping. Bacterial identification was carried out by established procedures (28, 41, 52). Serotyping on the basis of thermostable somatic O antigens was performed with the 66 antisera of the Penner scheme (41) and an additional 30 antisera to new serotypes not included in the Penner scheme.
Extraction of LPS using a miniphenol-water extraction procedure. Biomass harvested from two agar plates with confluent growth was washed three times in phosphate-buffered saline (PBS; pH 7.4; Oxoid) by centrifugation (5,000 × g for 5 min) and resuspended in 3.0 ml of sterile PBS (25). An aliquot of 0.75 ml was removed, centrifuged as before, and resuspended in 0.75 ml of water. An equivalent volume of 90% phenol (preheated to 65°C) was added, and samples were mixed for 1 min using an autovortex mixer and then incubated for 10 min at 65°C. At regular intervals the samples were mixed and, after cooling on ice, the samples were centrifuged (12,000 × g for 3 min). At this stage, separated layers were visible in the suspension. Residual phenol was removed from the aqueous phase by extracting three times with diethyl ether. The diethyl ether phase was discarded, and the water phase (containing the LPS) was placed in a fume cupboard for 1 h to allow the remaining diethyl ether to evaporate.
Comparison of LPS extraction techniques. To rule out the possibility that LPS extraction by the miniphenol-water procedure and LPS extraction by the hot phenol-water technique result in the purification of different subpopulations of LPS, materials extracted by the two methods were compared. Preparations of LPS were examined by polyacrylamide gel electrophoresis (PAGE) with silver staining, by immunoblotting, and by TLC with immunostaining with the ligands cholera toxin (CT), peanut agglutinin (PNA), and anti-GM1 antibodies. Furthermore, modifications of the miniphenol-water extraction procedure were performed with four C. jejuni strains, and the resulting material was included in the comparative studies. First, purified LPS (1.5 mg) was added to harvested C. jejuni biomass and a miniphenol-water extraction was performed on the resulting material. Second, a miniphenol-water extraction was performed on a pure LPS solution (2 mg/ml). Third, miniphenol-water-extracted LPS was subjected to enzymatic digestion with 80 µg of proteinase K (Sigma Chemical Co., St. Louis, Mo.) for 1 h at 60°C (17). Fourth, 0.2 mg each of DNase II (Sigma) and RNase A (Sigma) were incubated at 37°C overnight with the proteinase K-digested LPS extracts, and samples were then treated with proteinase K (0.8 mg). In addition, proteinase K-treated whole-cell (PKWC) extracts of C. jejuni strains were prepared as described by Hitchcock and Brown (17). Finally, boiled lysates were prepared by diluting harvested bacteria in PBS (pH 7.4) to an A600 of 0.3, followed by centrifugation (5,000 × g) and solubilization of the resulting pellet in 200 µl of PBS (for TLC) or in 200 µl of electrophoresis lysing buffer at 100°C for 1 h.
Additionally, we compared the LPS staining patterns of C. jejuni miniphenol-water-extracted LPS, pure LPS, and LPS prepared as described by Blake and Russell (12) by using the extraction procedure of Al-Hendy et al. (1).SDS-PAGE and immunoblotting. The discontinuous buffer system of Laemmli (21) was used to fractionate LPS extracts by sodium dodecyl sulfate (SDS)-PAGE using a stacking gel of 5% acrylamide and a separation gel of 15% acrylamide containing 3.2 M urea (BDH Laboratory Supplies, Poole, England) (39). After SDS-PAGE, the gels were fixed and the LPS was visualized by silver staining as described previously (54). Alternatively, LPSs fractionated by SDS-PAGE were electrotransferred from gels to nitrocellulose membranes (pore size, 0.45 µm; Bio-Rad Laboratories, Hercules, Calif.) (53). H. pylori LPS on nitrocellulose blots was visualized with an anti-Lewis Y monoclonal antibody (Signet Laboratories, Inc., Dedham, Mass.) against the O side chain (11) as the first antibody and horseradish peroxidase (HRP)-conjugated anti-mouse immunoglobulin M (IgM) (Sigma) as the second antibody. Alternatively, for detection of E. coli LPS reactions, a monoclonal antibody to E. coli core OS (anti-R3) was used as the first antibody (2) and an HRP-conjugated anti-mouse IgG (Sigma) was used as the second antibody.
TLC. Gangliosides (1-µg aliquots; Sigma) and LPS extracts (5-µl aliquots) were analyzed by TLC on precoated silica gel 60 glass plates (Merck, Darmstadt, Germany). Solvent systems consisting of chloroform-methanol-0.22% CaCl2 · 2H2O (50:45:10 [vol/vol/vol]) (47) and n-propanol-water-25% NH4OH (60:30:10 [vol/vol/vol]) (49, 59) were used as developers for gangliosides and LPSs, respectively. Gangliosides and LPS were visualized by spraying plates with resorcinol-HCl reagent (50).
Immunostaining. TLC with immunostaining was performed using the procedure of Saito et al. (47) as modified by Schwerer et al. (49). Briefly, developed TLC plates were dried for 30 min in a vacuum desiccator, fixed in 0.2% polyisobutylmethacrylate (Aldrich, Steinheim, Germany) in n-hexane (Merck) for 1.5 min, and dried as before. Nonspecific binding was reduced by submerging the plates for 1 h in a solution of PBS containing 0.3% gelatin (gelatin-PBS). Subsequently, lanes were overlaid with rabbit antiserum to ganglioside GM1 (Matreya Inc., Pleasant Gap, Pa.), diluted 1:100 in gelatin-PBS. Plates were incubated at 4°C overnight, washed three times with cold PBS, overlaid with peroxidase-conjugated anti-rabbit IgG (Sigma) diluted 1:500 in gelatin-PBS, and incubated at room temperature for 1 h with gentle rocking. The plates were washed with cold PBS, and the immunoreactants were visualized by use of an HRP development system (Bio-Rad Laboratories). Control experiments for antibody binding were performed whereby (i) preimmune rabbit serum was used instead of anti-GM1 antiserum and (ii) TLC plates were overlaid with the second antibody but not with the first antibody. Binding studies with CT-peroxidase conjugate (Sigma) and PNA-peroxidase conjugate (Kem-En-Tec, Copenhagen, Denmark) were performed under the same conditions as those described for immunostaining. However, only one overlay step with peroxidase-conjugated CT (1 µg/ml) or PNA (20 µg/ml) was necessary. Control experiments for CT and PNA ligand binding were performed using tetanus toxin C (TTC, which binds to disialosyl, or B series, gangliosides), which does not react with ganglioside GM1, instead of CT or PNA.
| |
RESULTS |
|---|
|
|
|---|
Assay validation.
Silver-stained SDS-PAGE gels comparing
miniphenol-water-extracted LPSs, LPSs extracted by a modification
of that procedure, and pure (hot phenol-water-extracted) LPSs from
C. jejuni serostrains O:19 and O:2, and from two
serotype O:41 strains (16971.94GSH and 28134.94GSH),
exhibited a pattern of bands migrating near the bottom of the gel.
These bands corresponded to low-Mr rough-form LPS composed of core OS and lipid A (Fig.
1A). As C. jejuni
high-Mr LPS is not visualized by the
silver-staining procedure of Tsai and Frasch (54),
immunoblotting was performed with C. jejuni typing antisera
(41). High-Mr LPS was visualized
for C. jejuni serostrain O:19, but as with silver
staining, only low-Mr LPS was apparent for
C. jejuni O:2 and serotype O:41 strains (data not shown).
Within the same strain, the miniphenol-water-extracted LPS, LPSs
extracted by a modification of that procedure, and pure LPS had
identical banding profiles, demonstrating that the different extraction
procedures and modifications used do not select for different
subpopulations of LPS. In addition, the pattern of staining in the
low-Mr region of the gel of the LPS extracted by
the method of Blake and Russell (12) was identical to the
profiles of both miniphenol-water-extracted LPS and purified LPS from
the same strain (data not shown). Similarly, for each individual strain of the four C. jejuni strains described above, there were no
differences in ligand or antibody affinities between LPS extracts
regardless of the extraction procedure used. As shown in Fig. 1B,
CT showed the same reactivity for each LPS extract, with the exception
of a weaker reaction with the boiled extract and PKWC lysate. The weaker reaction of boiled and PKWC lysates was a consistent finding with all the C. jejuni strains and ligands used; it
potentially reflects the presence of contaminating proteins. Supporting
this, Coomassie blue-stained SDS-PAGE gels of each preparation
demonstrated the presence of proteins in boiled extracts and PKWC
lysates, but not in the miniphenol-water LPS extracts (data not shown). In addition, no reactions were observed on control TLC plates incubated
with preimmune rabbit serum or on plates where the second antibody was
incubated in the absence of the first antibody. Moreover, immunoblots
of purified LPS and miniphenol-water-extracted LPS from H. pylori NCTC 11637 and E. coli J5 (UK) showed identical patterns of binding to corresponding antibodies, regardless of the LPS
extraction procedure used (data not shown).
|
|
Screening of the collection of C. jejuni serostrains for the GM1 epitope. To answer the question whether ganglioside-like epitopes are carried only by a limited number of Penner serotypes, a collection of C. jejuni serostrains was screened for the GM1 epitope using the rapid assay system.
As shown in Table 3, LPSs from five different serostrains reacted with all three ligands (O:4, O:5, O:13, O:36, and O:44), and isolates of each of these serotypes have been associated with GBS (7, 9, 14, 31, 33, 39). The LPSs of two of these C. jejuni serostrains have been chemically characterized and reported to mimic ganglioside GD1a (O:4) and ganglioside GM2 (O:36) (3, 10). In our assay, GM1 mimicry was detected in LPS from serostrain O:13. An isolate of this serotype has recently been associated for the first time with GBS (14). Furthermore, strong binding of each of the ligands tested was observed with LPSs of serostrains O:5 and O:44, suggesting for the first time the presence of a GM1 structure in the LPSs of these strains. Serostrain O:2 LPS was negative for reaction with each of the ligands tested, although LPS of C. jejuni NCTC 11168, an O:2 serotype, was found to bear GM1 mimicry (Table 2), consistent with the differences observed between these strains (24). Furthermore, serostrain O:23 LPS did not react with CT, PNA, or anti-GM1 antibodies, in contrast to serostrain O:36, despite sharing an identical core OS structure. This indicates a difference in GM2 ganglioside epitope expression in the two serostrains, and it can be proposed that the O side chain may have an effect on the expression of core OS in serostrains O:23 and O:36 (6). Also, the C. jejuni AZR6491 isolate (serotype O:23) reacted with CT in the validation study (Table 2). This suggests that the core OS of serostrain O:23 LPS may be different from that of LPSs from C. jejuni isolates of the same serotype, which is consistent with our preliminary chemical studies (5) and which has also been observed previously with C. jejuni O:19 isolates (7).
|
Screening for GM1 mimicry in C. jejuni
enteritis and GBS isolates.
The rapid assay technique was applied
to the testing of the C. jejuni isolates shown in Table
4. Based on reactions with CT, PNA, and
anti-GM1 antibodies, 3 of 5 (60%) serotype O:41 GBS isolates gave reactions that would be expected for the presence of
GM1-like mimicry. However, LPS preparations, including pure LPSs, from two C. jejuni O:41 GBS isolates (319.95 and
367.95) did not appear to exhibit a GM1 ganglioside
structure. Therefore, LPSs from these strains were tested for reaction
with anti-asialo-GM1, anti-GD2,
anti-GD3, and anti-GM2 antibodies and with a
ligand that binds to B series, or disialosyl, gangliosides. However, LPSs from both strains failed to react with any of the ligands tested,
indicating that LPSs from these strains do not resemble gangliosides
such as GM1, GM2, GD2,
GD3, and asialo-GM1. The possibility that LPSs
from these two serotype O:41 strains could mimic ganglioside GD1a cannot be ruled out. Although CT, PNA, and
anti-GM1 antibodies do not react with ganglioside
GD1a (39), all three ligands recognized LPS
from serostrain O:4, which exhibits mimicry of ganglioside GD1a (Table 3). However, microheterogeneity is present in
this LPS, with ~10% of the core OS molecules exhibiting
GM1 mimicry (3, 10), and thus the presence of
a GM1 epitope in serostrain O:4 LPS, rather than an
ability of the reagents to recognize GD1a epitopes,
accounts for the recognition by these three assay reagents. As ligands
for detecting mimicry of ganglioside GD1a are not
commercially available, whether the LPSs from the two serotype O:41
strains mimic ganglioside GD1a remains unanswered.
|
| |
DISCUSSION |
|---|
|
|
|---|
The association of GBS with preceding infection has led to a search for candidate bacterial antigens which may precipitate autoimmune responses in the host (16, 42, 56, 57). Gangliosides have been extensively studied as possible host antigens for autoimmune disease, since serum antibodies against gangliosides, especially GM1, are found in GBS sera, particularly when preceded by C. jejuni infection (15, 35, 44, 59, 60, 63). Molecular mimicry of gangliosides by core OSs of certain C. jejuni serotypes associated with GBS has been established (5, 7, 8, 10, 29, 31, 32, 56, 61), but LPSs from only a few C. jejuni GBS or MFS isolates have been studied at the molecular level. The main difficulty is that large amounts of biomass are required for LPS isolation, and this has not allowed for the screening of large numbers of strains. To overcome this problem, a laboratory-based rapid GM1 screening method that can be used to screen for cross-reactive epitopes in C. jejuni isolates was developed in the present study. Once the assay was validated, it was used to screen for GM1-bearing strains in a collection of 59 C. jejuni serostrains and was applied to the testing of a number of C. jejuni clinical isolates.
In the validation experiments, miniphenol-water-extracted LPS, LPSs from modifications of the miniphenol-water procedure, and pure LPS from the same strain had comparable banding patterns in SDS-PAGE, demonstrating that miniphenol-water extraction is a suitable LPS extraction procedure for use in the present study. In addition, LPS prepared as described by Blake and Russell (12), according to the procedure of Al-Hendy et al. (1), displayed low-Mr bands similar to those of miniphenol-water-extracted LPS and pure LPS when loaded at normal loading concentrations. However, higher loading concentrations (10 µg), as used in the original study of Al-Hendy et al., yielded bands in the high-Mr region which corresponded to aggregrates of LPS. Within the same strain, no differences in ligand or antibody affinities were observed among miniphenol-water-extracted LPS, LPSs from the miniphenol-water modified procedures, and pure LPS, again justifying the use of miniphenol-water extraction in our assay system. Additionally, ligand binding to ganglioside-mimicking pure LPSs was compared to ligand interactions with miniphenol-water-extracted LPSs from the same nine strains. In general, the ganglioside detection reagents had the same specificities for miniphenol-water-extracted LPSs and pure LPSs. The observation that PNA binding was reproducible only after proteinase K treatment of miniphenol-water extracts suggests that the use of this ligand may be justified only in tests using purer LPS. However, when LPS extraction was repeated using some of the strains, identical binding results were observed upon retesting, thus confirming the reproducibility of the assay. The reliability of the rapid assay was confirmed when miniphenol-water LPS extracts from strains with known ganglioside-like structures were tested (5, 39, 40, 49, 59, 61, 62).
Once the assay was validated and shown to be reliable and reproducible, 59 C. jejuni serostrains were screened for GM1-bearing LPS. Some serostrains with known ganglioside mimicry reacted with the ligands as expected, e.g., serostrains O:4, O:19, and O:36, which is consistent with GM1 or GM2 mimicry in these strains (7, 10, 29, 59, 62). C. jejuni serotypes that have been isolated from neuropathy patients and for which no LPS structural data is available include serotypes O:5, O:13, and O:44 and, in this study, were found to bear GM1-like epitopes. Based on recognition of PNA and anti-GM1 antibodies, LPSs from serostrains O:14, O:25, O:34, and O:43 were considered to exhibit asialo-GM1 mimicry. Interestingly, none of these serotypes have yet been found in association with GBS, although, to date, all neuropathy-associated strains bear LPSs which are sialylated.
Overall, 46 of 59 serostrains (78%) either failed to react with any of the three ligands used or were weakly positive with one ligand, suggesting that GM1 ganglioside-like epitopes are carried only by some Penner serotypes, which may account for the limited number of serotypes found in association with GBS. However, of the 46 serostrains that failed to react with any of the ligands tested, 11 have been found in association with GBS: serostrains O:1, O:2, O:15, O:16, O:18, O:20, O:23, O:24, O:30, O:37, and O:53 (31, 33). It is thought that the LPSs from these serotypes mimic more complex gangliosides that could not be detected with the reagents used in the present study. On the other hand, no serostrain with known GM1 mimicry failed to react with CT in combination with anti-GM1 antibodies, thus justifying the use of the rapid assay for GM1 screening of C. jejuni strains.
Subsequently, the assay was used for the screening of C. jejuni GBS and enteritis isolates for GM1 mimicry. The majority of the GBS-associated serotype O:41 strains had GM1-like structures in their LPSs, which is consistent with the GM1 mimicry previously reported for serotype O:41 GBS-associated strains (39, 40). Of the enteritis-associated strains, half had LPSs which had GM1 epitopes, and thus mimicry of ganglioside GM1 by core OS of C. jejuni strains is not limited to strains associated with GBS. This phenomenon has previously been reported by a number of groups (29, 34, 39, 46, 51). A study by Nachamkin et al. (34) showed that 26% of enteritis isolates were positive for the GM1-like epitope. Patients who develop enteritis and have isolates with ganglioside-mimicking LPS do not develop antiganglioside antibodies (37, 43, 51). The humoral immune response to neural cross-reactive epitopes in the LPSs of C. jejuni appears to be different in GBS than in uncomplicated enteritis (51). These factors suggest that other attributes of the host and/or bacterium in addition to ganglioside mimicry, contribute to the development of GBS or MFS.
The rapid screening assay described here has advantages over other systems reported previously (34, 46, 51). One assay involved spotting boiled cultures directly onto a nitrocellulose membrane and probing for GM1 epitopes with CT and PNA (34). First, in our rapid assay system, crude LPSs rather than boiled lysates are used, and thus there is no interference from non-LPS constituents. Second, the LPS is separated by TLC using silica as an adsorbent, a system whereby the conformation of the antigenic structure is unaltered, and this is considered not to be the case with the attachment of LPS to nitrocellulose membranes. Moreover, TLC separates LPS from contaminating components during the development process. In screening for GM1-bearing strains, Sheikh et al. (51) used purified LPS extracted by the hot phenol-water extraction procedure (55) and probed immunoblotted material with CT, PNA, and TTC. The main limitation of this assay was efficiency, as it was necessary to produce pure LPS and immunoblotting was required. Another assay, described by Sack et al. (46), was based on an inhibitory enzyme-labeled immunosorbent assay (ELISA) whereby strains with a GM1-like LPS bind to CT and inhibit the binding of control CT to ganglioside GM1. However, the assay had the disadvantage that crude boiled extracts were used, and the assay detected CT binding only, which can be misleading, and did not detect GM1 epitopes directly. Moreover, CT is a GM1 ligand, but it also cross-reacts with GM2 and asialo-GM1 gangliosides, and thus some of the strains detected by Sack et al. (46) may have possessed asialo-GM1 or GM2 epitopes. Nevertheless, the inhibition assay had the advantage that large numbers of strains could be tested quickly. In summary, the rapid screening assay described in the present study has the advantages of being reliable, reproducible, and able to screen large numbers of strains quickly; thus, the assay has attributes attractive for large-scale epidemiology studies.
| |
ACKNOWLEDGMENTS |
|---|
This study was supported by grants from the Irish Health Research Board (grant 86-95 to A.P.M. and grant 12/99 to M.M.P.).
We thank A. J. Lastovica (Cape Town, South Africa) for providing the C. jejuni O:41 strains and B. C. Jacobs (Rotterdam, The Netherlands) for providing the C. jejuni AZR 6491 isolate.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology, National University of Ireland, Galway, Ireland. Phone: 353-91-524411. Fax: 353-91-525700. E-mail: anthonymoran{at}nuigalway.ie.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Al-Hendy, A., P. Toivanen, and M. Skurnik. 1991. Rapid method for isolation and staining of bacterial lipopolysaccharide. Microbiol. Immunol. 35:331-333[Medline]. |
| 2. |
Appelmelk, B. J.,
J. J. Maaskant,
A. M. Verweij van Vught,
N. M. van der Meer,
B. G. Thijs, and D. M. McLaren.
1993.
Antigenic and immunogenic differences in lipopolysaccharides of Escherichia coli J5 vaccine strains of different origins.
J. Gen. Microbiol.
139:2641-2647 |
| 3. |
Aspinall, G. O.,
S. Fujimoto,
A. G. McDonald,
H. Pang,
L. A. Kurjanczyk, and J. L. Penner.
1994.
Lipopolysaccharide from Campylobacter jejuni associated with Guillain-Barré syndrome patients mimic human gangliosides in structure.
Infect. Immun.
62:2122-2125 |
| 4. | Aspinall, G. O., C. M. Lynch, H. Pang, R. T. Shaver, and A. P. Moran. 1995. Chemical structures of the core region of Campylobacter jejuni O:3 lipopolysaccharide and an associated polysaccharide. Eur. J. Biochem. 231:570-578[Medline]. |
| 5. | Aspinall, G. O., A. Mainkar, M. M. Prendergast, B. C. Jacobs, and A. P. Moran. 1997. Lipopolysaccharides from a neuropathy-associated infection from Campylobacter jejuni serotype O:23, p. 93-96. In A. J. Lastovica, D. G. Newell, and E. E. Lastovica (ed.), Campylobacter, Helicobacter and related organisms. Institute of Child Health and University of Cape Town, Cape Town, South Africa. |
| 6. | Aspinall, G. O., A. G. McDonald, and H. Pang. 1992. Structures of the O chains from lipopolysaccharides from Campylobacter jejuni serotypes O:23 and O:36. Carbohydr. Res. 231:13-20[CrossRef][Medline]. |
| 7. | Aspinall, G. O., A. G. McDonald, H. Pang, L. A. Kurjanczyk, and J. L. Penner. 1994. Lipopolysaccharides of Campylobacter jejuni serotype O:19. Structures of the core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 33:241-249[CrossRef][Medline]. |
| 8. | Aspinall, G. O., A. G. McDonald, T. S. Raju, H. Pang, L. A. Kurjanczyk, and J. L. Penner. 1993. Chemical structure of the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide. Eur. J. Biochem. 213:1029-1037[Medline]. |
| 9. |
Aspinall, G. O.,
A. G. McDonald,
T. S. Raju,
H. Pang,
S. D. Mills,
L. A. Kurjanczyk, and J. L. Penner.
1992.
Serological diversity and chemical structures of Campylobacter jejuni low-molecular-weight lipopolysaccharides.
J. Bacteriol.
174:1324-1332 |
| 10. | Aspinall, G. O., A. G. McDonald, T. S. Raju, H. Pang, A. P. Moran, and J. L. Penner. 1993. Chemical structure of the core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides. Eur. J. Biochem. 213:1017-1027[Medline]. |
| 11. | Aspinall, G. O., M. O. Monteiro, H. Pang, E. J. Walsh, and A. P. Moran. 1996. Lipopolysaccharide of the Helicobacter pylori type strain NCTC 11637 (ATCC 43504): structure of the O antigen and core oligosaccharide regions. Biochemistry 35:2489-2497[CrossRef][Medline]. |
| 12. |
Blake, D. C., and R. G. Russell.
1993.
Demonstration of lipopolysaccharide with O-polysaccharide chains among different heat-stable serotypes of Campylobacter jejuni by silver staining of polyacrylamide gels.
Infect. Immun.
61:5384-5387 |
| 13. | Butzler, J. P., P. Dekeyser, M. Detrain, and F. Dehaen. 1973. Related vibrio in stools. J. Pediatr. 82:493-495[CrossRef][Medline]. |
| 14. |
Endtz, H. P.,
C. W. Ang,
N. van den Braak,
B. Duim,
A. Rigter,
L. J. Price,
D. L. Woodward,
F. G. Rodgers,
W. M. Johnson,
J. A. Wegenaar,
B. C. Jacobs,
H. A. Verbrugh, and A. Belkum.
2000.
Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromes.
J. Clin. Microbiol.
38:2297-2301 |
| 15. |
Gregson, N. A.,
S. Koblar, and R. A. C. Hughes.
1993.
Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features.
Q. J. Med.
86:111-117 |
| 16. | Griffin, J. W., and T. W. H. Ho. 1993. The Guillain-Barré syndrome at 75: the Campylobacter connection. Ann. Neurol. 34:125-127[CrossRef][Medline]. |
| 17. |
Hitchcock, P. J., and T. M. Brown.
1983.
Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels.
J. Bacteriol.
154:269-277 |
| 18. |
Ho, T. W.,
B. Mishu,
C. Y. Li,
C. Y. Gao,
D. R. Cornblath,
J. W. Griffin,
A. K. Asbury,
M. J. Blaser, and G. M. McKhann.
1995.
Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies.
Brain
118:597-605 |
| 19. | Jacobs, B., H. Endtz, F. G. A. van der Meché, M. P. Hazenberg, H. A. M. Achtereekte, and P. A. van Doorn. 1995. Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann. Neurol. 37:260-264[CrossRef][Medline]. |
| 20. |
Kuroki, S.,
T. Saida,
M. Nukina,
T. Haruta,
M. Yoshiota,
Y. Kobayashi, and H. Nakanishi.
1993.
Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain -N-acetylglucosamine residues.
Ann. Neurol.
33:243-247[CrossRef][Medline].
|
| 21. | Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227:680-685[CrossRef][Medline]. |
| 22. | Lastovica, A. J., E. A. Goddard, and A. C. Argent. 1997. Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni O:41 strains. J. Infect. Dis. 176(Suppl. 2):139-143[CrossRef]. |
| 23. |
Lindblom, G. B.,
B. Kaijser, and E. Sjogren.
1989.
Enterotoxin production and serogroups of Campylobacter jejuni and Campylobacter coli from patients with diarrhea and from healthy laying hens.
J. Clin. Microbiol.
27:1272-1276 |
| 24. | Linton, D., A. V. Karlyshev, P. G. Hitchen, H. R. Morris, A. Dell, N. A. Gregson, and B. W. Wren. 2000. Multiple N-acetylneuraminic acid synthetase (neuB) genes in Campylobacter jejuni: identification and characterization of the gene involved in sialylation of lipo-oligosaccharide. Mol. Microbiol. 35:1120-1134[CrossRef][Medline]. |
| 25. |
Mills, S. D.,
L. A. Kurjanczyk, and J. L. Penner.
1992.
Antigenicity of Helicobacter pylori lipopolysaccharides.
J. Clin. Microbiol.
30:3175-3180 |
| 26. | Mishu, B., and M. J. Blaser. 1993. Role of infection due to Campylobacter jejuni in the initiation of Guillain-Barré syndrome. Clin. Infect. Dis. 17:104-108[Medline]. |
| 27. | Monos, D. S., M. Papaioakim, T. W. Ho, C. Y. Li, and G. M. McKhann. 1997. Differential distribution of HLA alleles in two forms of Guillain-Barré syndrome. J. Infect. Dis. 176(Suppl. 2):180-182[CrossRef]. |
| 28. | Moran, A. P., and T. U. Kosunen. 1989. Serological analysis of the heat-stable antigens involved in serotyping Campylobacter jejuni and Campylobacter coli. APMIS 97:253-260[Medline]. |
| 29. | Moran, A. P., and D. T. O'Malley. 1995. Potential role of lipopolysaccharides of Campylobacter jejuni in the development of Guillain-Barré syndrome. J. Endotoxin Res. 2:233-235. |
| 30. | Moran, A. P., and J. L. Penner. 1999. Serotyping of Campylobacter jejuni based on heat-stable antigens: relevance, molecular basis and implications in pathogenesis. J. Appl. Microbiol. 86:361-377[CrossRef][Medline]. |
| 31. | Moran, A. P., M. M. Prendergast, and B. J. Appelmelk. 1996. Molecular mimicry of host structures by bacterial lipopolysaccharide and its contribution to disease. FEMS Immunol. Med. Microbiol. 16:105-115[CrossRef][Medline]. |
| 32. |
Moran, A. P.,
E. T. Rietschel,
T. U. Kosunen, and U. Zahringer.
1991.
Chemical characterization of Campylobacter jejuni lipopolysaccharides containing N-acetylneuraminic acid and 2,3-diamino-2,3-dideoxy-D-glucose.
J. Bacteriol.
173:618-626 |
| 33. |
Nachamkin, I.,
B. M. Allos, and T. Ho.
1998.
Campylobacter species and Guillain-Barré syndrome.
Clin. Microbiol. Rev.
11:555-567 |
| 34. | Nachamkin, I., H. Ung, A. P. Moran, D. Yoo, M. M. Prendergast, M. A. Nicholson, K. A. Sheikh, T. W. Ho, A. K. Asbury, G. M. McKhann, and J. W. Griffin. 1999. Ganglioside GM1 mimicry in Campylobacter strains from sporadic infections in the United States. J. Infect. Dis. 179:1183-1189[CrossRef][Medline]. |
| 35. | Nobile-Orazio, E., M. Carpo, N. Meucci, M. P. Grassi, E. Capitani, M. Sciacco, A. Mangoni, and G. Scarlato. 1992. Guillain-Barré syndrome associated with high titres of anti-GM1 antibodies. J. Neurol. Sci. 109:200-206[CrossRef][Medline]. |
| 36. | Obayashi, H., T. Saida, S. Kuroki, M. Nukina, and Y. Nishitani. 1993. Guillain-Barré syndrome and Campylobacter jejuni infection. Shinkei Naika 38:431-438. |
| 37. | Oomes, P. G., B. C. Jacobs, M. P. H. Hazenberg, J. R. J. Bänffer, and F. G. A. van der Meché. 1995. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry. Ann. Neurol. 38:170-175[CrossRef][Medline]. |
| 38. | Penner, J. L., J. N. Hennessy, and R. V. Congi. 1983. Serotyping of Campylobacter jejuni and Campylobacter coli on the basis of thermostable antigens. Eur. J. Clin. Microbiol. 2:78-83. |
| 39. |
Prendergast, M. M.,
A. J. Lastovica, and A. P. Moran.
1998.
Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain-Barré syndrome exhibit mimicry of GM1 ganglioside.
Infect. Immun.
66:3649-3655 |
| 40. |
Prendergast, M. M.,
H. J. Willison, and A. P. Moran.
1999.
Human monoclonal IgM antibodies to GM1 ganglioside show diverse cross-reactivity with lipopolysaccharides of Campylobacter jejuni strains associated with Guillain-Barré syndrome.
Infect. Immun.
67:3698-3701 |
| 41. |
Preston, M. A., and J. L. Penner.
1987.
Structural and antigenic properties of lipopolysaccharide from serotype reference strains of Campylobacter jejuni.
Infect. Immun.
55:1806-1812 |
| 42. | Rees, J. H., N. A. Gregson, P. L. Griffiths, and R. A. C. Hughes. 1993. Campylobacter jejuni and Guillain-Barré syndrome. Q. J. Med. 86:623-634. |
| 43. | Rees, J. H., N. A. Gregson, and R. A. C. Hughes. 1995. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann. Neurol. 38:809-816[CrossRef][Medline]. |
| 44. | Rees, J. H., and R. A. C. Hughes. 1994. Campyobacter jejuni and Guillain-Barré syndrome. Ann. Neurol. 35:248-249[CrossRef][Medline]. |
| 45. |
Rees, J. H.,
S. E. Soudain,
N. A. Gregson, and R. A. C. Hughes.
1995.
Campylobacter jejuni infection and Guillain-Barré syndrome.
N. Engl. J. Med.
333:1374-1379 |
| 46. |
Sack, D. A.,
A. J. Lastovica,
S. H. Chang, and G. Pazzaglia.
1998.
Microtiter assay for detecting Campylobacter spp. and Helicobacter pylori with surface gangliosides which bind cholera toxin.
J. Clin. Microbiol.
36:2043-2045 |
| 47. | Saito, M., N. Kasai, and R. K. Yu. 1985. In situ immunological determination of basic carbohydrate structures of gangliosides on thin-layer plates. Anal. Biochem. 148:54-58[CrossRef][Medline]. |
| 48. | Salloway, S., L. A. Mermel, M. Seamens, G. O. Aspinall, J. E. Nam Shin, L. A. Kurjanczyk, and J. L. Penner. 1996. Miller Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3. Infect. Immun. 64:2945-2949[Abstract]. |
| 49. |
Schwerer, B.,
A. Neisser,
R. J. Polt,
H. Bernheimer, and A. P. Moran.
1995.
Antibody cross-reactivities between gangliosides and lipopolysaccharides of Campylobacter jejuni serotypes associated with Guillain-Barré syndrome.
J. Endotoxin Res.
2:395-403 |
| 50. |
Schwimmer, S., and A. Bevenue.
1956.
Reagent for differentiation of 1,4- and 1,6-linked glucosaccharides.
Science
123:543-544 |
| 51. |
Sheikh, K. A.,
I. Nachamkin,
T. W. Ho,
H. J. Willison,
J. Veitch,
H. Ung,
M. Nicholson,
C. Y. Li,
H. S. Wu,
B. Q. Shen,
D. R. Cornblath,
A. K. Asbury,
G. M. McKhann, and J. W. Griffin.
1998.
Campylobacter jejuni lipopolysaccharide in Guillain-Barré syndrome: molecular mimicry and host susceptibility.
Neurology
51:371-378 |
| 52. |
Skirrow, M. B., and J. Benjamin.
1980.
Differentiation of enteropathogenic Campylobacter.
J. Clin. Pathol.
33:1122 |
| 53. |
Towbin, H.,
T. Staehelin, and J. Gordon.
1979.
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Proc. Natl. Acad. Sci. USA
76:4350-4354 |
| 54. | Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119:115-119[CrossRef][Medline]. |
| 55. | Westphal, O., and K. Jann. 1965. Bacterial lipopolysaccharides: extraction with phenol water and further applications of the procedure. Methods Carbohydr. Chem. 5:83-92. |
| 56. | Willison, H. J., and P. G. E. Kennedy. 1993. Gangliosides and bacterial toxins in Guillain-Barré syndrome. J. Neuroimmunol. 46:105-112[CrossRef][Medline]. |
| 57. | Yuki, N. 1994. Pathogenesis of axonal Guillain-Barré syndrome: hypothesis. Muscle Nerve 17:680-682[CrossRef][Medline]. |
| 58. | Yuki, N., S. Handa, T. Tai, M. Takahashi, K. Saito, Y. Tsujino, and T. Taki. 1995. Ganglioside-like epitopes of lipopolysaccharide from Campylobacter jejuni (Pen 19) in three isolates from patients with Guillain-Barré syndrome. J. Neurol. Sci. 130:112-116[CrossRef][Medline]. |
| 59. | Yuki, N., S. Handa, T. Taki, T. Kasama, M. Takihashi, K. Saito, and T. Miyatake. 1992. Cross-reactive antigen between nervous tissue and a bacterium elicits Guillain-Barré syndrome: molecular mimicry between ganglioside GM1 and lipopolysaccharide from Penner's serotype 19 of Campylobacter jejuni. Biomed. Res. 13:451-453. |
| 60. |
Yuki, N.,
S. Sato,
T. Itoh, and T. Miyatake.
1991.
HLA-B35 and acute axonal polyneuropathy following Campylobacter infection.
Neurology
41:1561-1563 |
| 61. |
Yuki, N.,
T. Taki,
F. Inagaki,
T. Kasama,
T. M. Takahashi,
M. K. Saito,
S. Handa, and T. Miyatake.
1993.
A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure.
J. Exp. Med.
178:1771-1775 |
| 62. |
Yuki, N.,
T. Taki,
M. Takahashi,
K. Saito,
T. Tai,
T. Miyatake, and S. Handa.
1994.
Penner's serogroup 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1a epitope.
Infect. Immun.
62:2101-2103 |
| 63. |
Yuki, N.,
H. Yoshino,
S. Sato, and T. Miyatake.
1990.
Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis.
Neurology
40:1900-1902 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»